RedHill Biopharma Ltd.
RDHLNASDAQHealthcare● Active
$0.88
$-0.15(-14.22%)
Market Cap$2750000
P/E Ratio—
52W High$3.31
52W Low$0.71
RedHill Biopharma Ltd. (RDHL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RDHL · earnings · updated Jun 10, 2026
Latest Earnings
Q3 FY2025Report Date: Sep 5, 2025EPS Actual
-$1.15
Revenue
$0.00B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Sep 5, 2025
After Market Close
RDHL reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 20, 2026 | -$690.00 | — | — | — | $0.00B | — |
| ◌ Q3 FY2026 | Aug 13, 2026 | -$352.86 | — | — | — | $0.02B | — |
| ◌ Q2 FY2026 | Apr 9, 2026 | -$435.00 | — | — | — | $0.02B | — |
| ◌ Q1 FY2026 | Mar 30, 2026 | -$435.00 | — | — | — | $0.02B | — |
| — Q3 FY2025 | Sep 5, 2025 | — | -$1.15 | — | $0.00B | — | — |
| ◌ Q2 FY2025 | Jun 14, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | Apr 10, 2025 | — | — | — | — | — | — |
| — Q4 FY2024 | Oct 3, 2024 | — | $900.00 | — | — | — | — |
Q3 FY2026
Aug 20, 2026
EPS Actual
—
EPS Est.
-$690.00
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$352.86
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 9, 2026
EPS Actual
—
EPS Est.
-$435.00
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 30, 2026
EPS Actual
—
EPS Est.
-$435.00
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 5, 2025
EPS Actual
-$1.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Jun 14, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 10, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Oct 3, 2024
EPS Actual
$900.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2029 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2029 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $-10.00 | $-10.00 | $-10.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Sep 5, 2025 | — | $1.23 | $1.43 | +16.26% |
| — Q4 FY2024 | Oct 3, 2024 | — | $8.04 | $8.15 | +1.37% |
| ▼ Q3 FY2024 | Aug 29, 2024 | -566.7% | $8.36 | $8.62 | +3.11% |
| ▼ Q1 FY2024 | Feb 12, 2024 | -566.7% | $14.90 | $14.52 | -2.55% |
Q3 FY2025+16.26%
Report Date
Sep 5, 2025
EPS Beat/Miss
—
Price Before
$1.23
Price After
$1.43
Q4 FY2024+1.37%
Report Date
Oct 3, 2024
EPS Beat/Miss
—
Price Before
$8.04
Price After
$8.15
Q3 FY2024+3.11%
Report Date
Aug 29, 2024
EPS Beat/Miss
-566.7%
Price Before
$8.36
Price After
$8.62
Q1 FY2024-2.55%
Report Date
Feb 12, 2024
EPS Beat/Miss
-566.7%
Price Before
$14.90
Price After
$14.52
Avg Miss Reaction+0.28%
Beat Rate0 / 4 quarters
Largest Move+16.26% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RDHL ends December
RedHill Biopharma Ltd. (RDHL) most recently reported earnings on September 5, 2025 for Q3 FY2025, posting EPS of $-1.15 (in line with the analyst consensus of —).
Each quarter, investors track RDHL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RDHL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RDHL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RDHL earnings · 4 questionsRedHill Biopharma Ltd.'s next earnings report is expected around TBD. RDHL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RDHL historically reports after market close (AMC).
RDHL earnings datewhen is RDHL earningsRDHL next earnings datewhen does RDHL report earningsRDHL earnings calendar
▸ Source: FMP · RedHill Biopharma Ltd. SEC filings · US GAAP · RedHill Biopharma Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026